Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Arcturus Therapeutics in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo forecasts that the biotechnology company will post earnings per share of ($0.80) for the quarter. The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same period in the previous year, the business earned ($0.61) EPS.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright restated a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of "Buy" and a consensus target price of $66.75.

Arcturus Therapeutics Trading Up 4.1 %

Shares of NASDAQ:ARCT traded up $0.68 during trading on Thursday, hitting $17.42. 402,475 shares of the company were exchanged, compared to its average volume of 396,941. The stock has a market cap of $471.91 million, a price-to-earnings ratio of -7.85 and a beta of 2.63. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The firm has a fifty day moving average price of $17.27 and a two-hundred day moving average price of $19.74.

Institutional Trading of Arcturus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth $42,000. China Universal Asset Management Co. Ltd. raised its stake in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after purchasing an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Arcturus Therapeutics during the 2nd quarter worth approximately $142,000. Point72 DIFC Ltd bought a new position in shares of Arcturus Therapeutics during the second quarter worth approximately $188,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $191,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.